retatrutide peptide clinical trial A new from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Lilly orforglipron oral GLP-1 phase

Eli Lilly and Company Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

Urva, S

They found that even without causing weight loss, retatrutide had anti-tumor effects that were similar to the currently used (and incredibly expensive) immunotherapy.[ref] A 5-year mortality study in colon cancer patients showed that GLP-1 RA use decreased mortality risk by 60% in obese patients.[ref] Animal studies may show the mechanism

Here's what my "transformation timeline" looked like: Week 1: For the first time in months, the aggressive shedding started to slow down

10.2337/db12-1498 129 WingR

Saxenda is not indicated as a lipid-lowering agent in the manner of statins or fibrates